Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

2021579 citationsJournal Articlebronze Open Access

Authors

Aaron B. Waxman · Brigham and Women's Hospital

Ricardo Restrepo‐Jaramillo · University of South Florida

Thenappan Thenappan · University of Minnesota System

Ashwin Ravichandran · St. Vincent Hospital

Peter A. Engel · Christ Hospital

Abubakr Bajwa · Saint Vincent Health System

Roblee P. Allen

Abstract

In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil improved exercise capacity from baseline, assessed with the use of a 6-minute walk test, as compared with placebo. (Funded by United Therapeutics; INCREASE ClinicalTrials.gov number, NCT02630316.).

Topics & Keywords

Pulmonary Hypertension Research and Treatments Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Transplantation: Methods and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 4, pp. 325-334

DOI: 10.1056/nejmoa2008470

Field-Weighted Citation Impact: 61.30